CN117529317A - 吲哚、6-和7-氮杂吲哚衍生物作为铁死亡调节的细胞死亡的抑制剂的用途 - Google Patents

吲哚、6-和7-氮杂吲哚衍生物作为铁死亡调节的细胞死亡的抑制剂的用途 Download PDF

Info

Publication number
CN117529317A
CN117529317A CN202280024110.4A CN202280024110A CN117529317A CN 117529317 A CN117529317 A CN 117529317A CN 202280024110 A CN202280024110 A CN 202280024110A CN 117529317 A CN117529317 A CN 117529317A
Authority
CN
China
Prior art keywords
alkyl
aryl
hydrogen atom
heterocyclyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280024110.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴赫
A·孔德
C·戴勒霍兹
M-T·迪芒什-波埃尔
P·高简
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocean Life Co
School Of Advanced Studies In Public Health
Centre National de la Recherche Scientifique CNRS
Universite de Rennes 1
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Claude Bernard Lyon 1
Original Assignee
Ocean Life Co
Centre National de la Recherche Scientifique CNRS
Universite de Rennes 1
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean Life Co, Centre National de la Recherche Scientifique CNRS, Universite de Rennes 1, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Universite Claude Bernard Lyon 1 filed Critical Ocean Life Co
Publication of CN117529317A publication Critical patent/CN117529317A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280024110.4A 2021-01-25 2022-01-25 吲哚、6-和7-氮杂吲哚衍生物作为铁死亡调节的细胞死亡的抑制剂的用途 Pending CN117529317A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305085.9 2021-01-25
EP21305085 2021-01-25
PCT/EP2022/051650 WO2022157392A1 (en) 2021-01-25 2022-01-25 Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death

Publications (1)

Publication Number Publication Date
CN117529317A true CN117529317A (zh) 2024-02-06

Family

ID=74553738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280024110.4A Pending CN117529317A (zh) 2021-01-25 2022-01-25 吲哚、6-和7-氮杂吲哚衍生物作为铁死亡调节的细胞死亡的抑制剂的用途

Country Status (6)

Country Link
US (1) US20240116923A1 (https=)
EP (1) EP4281070A1 (https=)
JP (1) JP2024506530A (https=)
CN (1) CN117529317A (https=)
CA (1) CA3205853A1 (https=)
WO (1) WO2022157392A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250127084A (ko) 2022-12-02 2025-08-26 시비라이프 조절된 괴사 억제제와 n-아세틸시스테인의 상승작용적 조합
WO2025078659A1 (en) 2023-10-12 2025-04-17 Seabelife Method and kit for inducing cell differentiation, and regulated necrotic cell death inhibitor for use for regenerating damaged tissues
WO2025206255A1 (ja) * 2024-03-29 2025-10-02 富士フイルム株式会社 被験物質の評価方法および被験物質の評価キット

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011248175A1 (en) * 2010-05-06 2012-10-25 Merck Sharp & Dohme Corp. Aza-Indole derivatives useful as modulators of FAAH
WO2017054216A1 (zh) * 2015-10-01 2017-04-06 史利利 电磁炉及线圈盘
WO2017064216A1 (en) * 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) N1- and n7-substituted sibiriline derivatives and their use as inhibitor of cellular necroptosis
ES2885474T3 (es) * 2015-10-13 2021-12-13 Inst Nat Sante Rech Med Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular
WO2019106434A1 (en) * 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
AU2019390478A1 (en) * 2018-11-27 2021-07-08 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
BR112021017831A2 (pt) * 2019-03-11 2021-11-30 Collaborative Medicinal Dev Llc Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose

Also Published As

Publication number Publication date
JP2024506530A (ja) 2024-02-14
EP4281070A1 (en) 2023-11-29
US20240116923A1 (en) 2024-04-11
CA3205853A1 (en) 2022-07-28
WO2022157392A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
CN101827593B (zh) 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
CN101687883B (zh) 囊性纤维化跨膜传导调节因子的调节剂
CN117529317A (zh) 吲哚、6-和7-氮杂吲哚衍生物作为铁死亡调节的细胞死亡的抑制剂的用途
JP7382973B2 (ja) ピリジニル及びピラジニル－（アザ）インドールスルホンアミド
AU2018278311B2 (en) IRE1 small molecule inhibitors
CN105968115B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
CN104797581B (zh) 杂芳基炔烃化合物及其应用
JP2018522867A (ja) 縮合二環式ピリミジン誘導体およびこれらの使用
WO2018205938A1 (zh) Parp抑制剂、其药物组合物、制备方法和应用
CN107406390A (zh) 单羧酸转运蛋白调节剂及其用途
CN106604919B (zh) 6-((6,7-二甲氧基喹唑啉-4-基)氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
CN113056271A (zh) 法尼醇x受体激动剂及其用途
CN113811324A (zh) 小分子局部黏着斑激酶(fak)抑制剂
WO2025021148A1 (zh) Wrn抑制剂及其药物组合物和应用
AU2016369835A1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
CN106146473B (zh) 一种抗血管新生化合物
CN117247387A (zh) 一种芳杂环类化合物及其制备方法
WO2025093058A1 (zh) 2-氧代吲哚啉类衍生物及其制备方法和应用
WO2018045969A1 (zh) 活化腺苷单磷酸活化蛋白激酶之化合物
WO2025007928A1 (zh) 一种吲哚类化合物及其制备方法和用途
TW202412778A (zh) 一種脯氨醯羥化酶抑制劑及其用途
JP2025509950A (ja) Ｐｉ３ｋ阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法
TW202448441A (zh) 脯氨醯羥化酶抑制劑及其用途
WO2024104317A1 (zh) 抑制15-pgdh的化合物及其用途
TW202404978A (zh) 一種調控１５－ｐｇｄｈ活性的化合物、包含其的組合物及它們的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20251027

Address after: Roskov, France

Applicant after: Ocean Life Co.

Country or region after: France

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant after: SORBONNE UNIVERSITE

Applicant after: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Applicant after: University CLAUDE BERNARD LYON

Applicant after: University RENNES

Applicant after: School of advanced studies in public health

Address before: Roskov, France

Applicant before: Ocean Life Co.

Country or region before: France

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant before: SORBONNE UNIVERSITE

Applicant before: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Applicant before: University CLAUDE BERNARD LYON

Applicant before: University RENNES